Skip to main content
RYVU Therapeutics S.A. logo

RYVU Therapeutics S.A. — Investor Relations & Filings

Ticker · RVU ISIN · PLSELVT00013 LEI · 2594003WO9Q9HHAFL031 WAR Professional, scientific and technical activities
Open in API
Filings indexed 803 across all filing types
Latest filing 2025-06-12 Major Shareholding Noti…
Country PL Poland
Listing WAR RVU

About RYVU Therapeutics S.A.

https://ryvu.com/

Ryvu Therapeutics is a clinical-stage drug discovery and development company specializing in novel small molecule therapies for oncology. The company's research focuses on emerging biological targets and pathways, including kinase inhibition, synthetic lethality, and immuno-oncology, to develop precise cancer treatments. Its pipeline features several candidates in various stages of development. Key clinical-stage assets include Romaciclib (RVU120), a selective CDK8/19 kinase inhibitor for treating hematologic malignancies like acute myeloid leukemia (AML) and myelofibrosis, and Dapolsertib (MEN1703), a PIM/FLT3 inhibitor. The company also advances preclinical programs, such as an MTA-cooperative PRMT5 inhibitor for solid tumors with MTAP deletion.

Recent filings

Filing Released Lang Actions
Zawiadomienia od osób blisko związanych z osobą pełniącą obowiązki zarządcze w Spółce / Notifications from persons closely associated with a person discharging managerial responsibilities in the Co...
Major Shareholding Notification Classification · 1% confidence The document text is very short (714 characters) and explicitly states that it is reporting the receipt of two notifications ('powiadomień') made under Article 19(1) of the MAR Regulation concerning transactions by persons closely associated with a member of the Supervisory Board (Mr. Tadeusz Wesołowski). Crucially, the last sentence states: 'Treść powiadomień stanowi załącznik do niniejszego raportu' (The content of the notifications constitutes an attachment to this report). This structure—a brief announcement referencing attached insider transaction details—fits the definition of a Director's Dealing report (DIRS) or, given the context of regulatory reporting of insider transactions, it could potentially be classified as a general Regulatory Filing (RNS). However, since the core subject is the transaction by a director/executive (Wiceprzewodniczący Rady Nadzorczej), DIRS is the most specific fit for insider trading reports, even if this specific document is just the cover announcement. Since the document is an announcement about insider transactions by a director, DIRS is the most appropriate code.
2025-06-12 Polish
Załącznik_Prezentacja_EN
Investor Presentation Classification · 0% confidence
2025-06-12 Polish
Załącznik_Prezentacja_PL
Investor Presentation Classification · 0% confidence
2025-06-12 Polish
Dane dotyczące RVU120 prezentowane podczas Kongresu Europejskiego Towarzystwa Hematologicznego 2025 (EHA) / Data on RVU120 presented at the 2025 European Hematology Association Congress - Content ...
Regulatory Filings Classification · 1% confidence The document announces that Ryvu Therapeutics S.A. will be presenting data on its drug RVU120 at the 2025 European Hematology Association Congress (EHA). It details the specific posters and oral presentations, including preliminary clinical trial results (RIVER-81, POTAMI-61, RIVER-52) and preclinical findings. Crucially, the text states: 'The presentation related to the presented posters is attached to this report' and later mentions that posters are available via the EHA platform or the Ryvu website, and that management will host a webinar to discuss the data. This structure—announcing data presentation at a conference and referencing attached/available materials—strongly suggests this is an announcement about upcoming or recently presented research findings, rather than the full, comprehensive report itself (like a 10-K or IR). Since it is an announcement detailing scientific data presentation, it fits best under Investor Presentation (IP) if it were the slides themselves, but as an announcement *about* the presentation and attached materials, it functions as a general update or press release regarding investor/research information. Given the options, this is a detailed update on clinical progress shared with investors/the public, which aligns closely with the scope of an Investor Presentation (IP) or a general Regulatory Filing (RNS). However, because it is a detailed summary of scientific data being presented at a major medical congress, it is most accurately classified as an Investor Presentation (IP) or a detailed scientific update often bundled with investor relations materials, rather than a generic RNS. Since it is not a formal regulatory filing like a 10-K or IR, and it is more detailed than a simple Earnings Release (ER), IP is the strongest fit for disseminating detailed scientific/clinical progress to the investment community.
2025-06-12 English
Dane dotyczące RVU120 prezentowane podczas Kongresu Europejskiego Towarzystwa Hematologicznego 2025 (EHA) / Data on RVU120 presented at the 2025 European Hematology Association Congress - Content ...
Report Publication Announcement Classification · 1% confidence The document is a corporate announcement from Ryvu Therapeutics S.A. detailing the data presentations (oral and poster) scheduled for the European Hematology Association (EHA) 2025 Congress in Milan. It summarizes preliminary clinical trial results for their drug RVU120 across various hematological conditions (AML, MF, MDS). The text explicitly mentions that the presentation materials for the posters are attached ('Prezentacja dotycząca prezentowanych posterów stanowi załącznik do niniejszego raportu') and provides a link where the poster presentations are available ('Prezentacje posterowe są już dostępne poprzez platformę EHA oraz na stronie korporacyjnej Ryvu'). Furthermore, it announces a separate management webinar. Since the core content is an announcement about presenting data/materials at a conference, and it references attached/available presentations, this strongly indicates a Report Publication Announcement (RPA) or potentially an Investor Presentation (IP) if the content itself were the presentation slides. Given the structure—a brief announcement summarizing data points and pointing to the actual presentations/posters—RPA is the most fitting category, as it announces the publication/presentation of research findings. It is not the full Annual Report (10-K), Interim Report (IR), or a standard Earnings Release (ER).
2025-06-12 Polish
Zawiadomienie Augebit
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction(s) referred to in Article 19(1) of the MAR Regulation). It details transactions (Zbycie - Disposal) involving shares ('akcje') conducted by a person closely associated with a manager (Tadeusz Wesołowski - Wiceprzewodniczący Rady Nadzorczej) of the issuer (RYVU THERAPEUTICS SPÓŁKA AKCYJNA). This structure and content specifically relate to insider trading disclosures required under the Market Abuse Regulation (MAR), which mandates reporting of transactions by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. This directly corresponds to the definition of Director's Dealing (DIRS).
2025-06-09 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.